TY  - GEN
AU  - Kropff,Martin
AU  - Baylon,Honorata Giongco
AU  - Hillengass,Jens
AU  - Robak,Tadeusz
AU  - Hajek,Roman
AU  - Liebisch,Peter
AU  - Goranov,Stefan
AU  - Hulin,Cyrille
AU  - Bladé,Joan
AU  - Caravita,Tommaso
AU  - Avet-Loiseau,Herve
AU  - Moehler,Thomas M
AU  - Pattou,Claire
AU  - Lucy,Lela
AU  - Kueenburg,Elisabeth
AU  - Glasmacher,Axel
AU  - Zerbib,Robert
AU  - Facon,Thierry
TI  - Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
SN  - 1592-8721
PY  - 2012///0906
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenesis Inhibitors
KW  - therapeutic use
KW  - Antineoplastic Agents, Hormonal
KW  - Dexamethasone
KW  - Disease Progression
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - International Agencies
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Neoplasm Recurrence, Local
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Prospective Studies
KW  - Remission Induction
KW  - Salvage Therapy
KW  - Survival Rate
KW  - Thalidomide
N1  - Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.3324/haematol.2011.044271
ER  -